Literature DB >> 20068287

Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism.

Chiaki Kumata1, Masahide Mizobuchi, Hiroaki Ogata, Fumihiko Koiwa, Ai Nakazawa, Fumiko Kondo, Yoshiyuki Kadokura, Eriko Kinugasa, Tadao Akizawa.   

Abstract

BACKGROUND/AIMS: Fibroblast growth factor 23 (FGF23) has been shown to suppress parathyroid hormone (PTH) secretion. alpha-Klotho has been demonstrated to function as a fibroblast growth factor receptor (FGFR) cofactor for FGF23. Thus, both alpha-Klotho and FGFR may play roles in PTH synthesis and/or secretion. Functions of alpha-Klotho and FGFR in secondary hyperparathyroidism (SHPT) remain to be studied. The present studies explore the role of alpha-Klotho and FGFR in SHPT.
METHODS: Hyperplastic parathyroid glands (n = 44) were obtained from patients with SHPT.
RESULTS: Immunohistochemical study showed that both alpha-Klotho and FGFR1c expression in hyperplastic glands was significantly decreased compared with that in normal glands (Klotho p < 0.01, and FGFR1c p < 0.05). A significant positive correlation was observed between alpha-Klotho and FGFR1c (r(2) = 0.375, p < 0.01) indicating a cooperative system. Both alpha-Klotho (r(2) = 0.235, p < 0.05) and FGFR1c (r(2) = 0.181, p < 0.05) correlated positively with the calcium-sensing receptor (CaR), which plays an important role in the development of SHPT. In addition, expression of alpha-Klotho correlated negatively with parathyroid cell proliferation, as confirmed by Ki67 staining (r(2) = 0.148, p < 0.05).
CONCLUSION: Decreased expression of alpha-Klotho and FGFR1c in parallel with CaR expression and parathyroid cell growth may be involved in the pathogenesis of SHPT. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068287     DOI: 10.1159/000274483

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  19 in total

Review 1.  Role of Klotho in aging, phosphate metabolism, and CKD.

Authors:  George B John; Chung-Yi Cheng; Makoto Kuro-o
Journal:  Am J Kidney Dis       Date:  2011-04-15       Impact factor: 8.860

Review 2.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

Review 3.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 4.  Renal and extrarenal actions of Klotho.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

Review 5.  FGF23 and the parathyroid glands.

Authors:  Justin Silver; Tally Naveh-Many
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

6.  A correlation between decreased parathyroid α-Klotho and fibroblast growth factor receptor 1 expression with pathological category and parathyroid gland volume in dialysis patients.

Authors:  Junfang Yan; Chen Jingbo; Deguang Wang; Shengxue Xie; Liang Yuan; Xing Zhong; Li Hao
Journal:  Int Urol Nephrol       Date:  2015-03-07       Impact factor: 2.370

Review 7.  The role of FGF23 in CKD--with or without Klotho.

Authors:  Hirotaka Komaba; Masafumi Fukagawa
Journal:  Nat Rev Nephrol       Date:  2012-06-19       Impact factor: 28.314

8.  Involvement of α-klotho, fibroblast growth factor-, vitamin-D- and calcium-sensing receptor in 53 patients with primary hyperparathyroidism.

Authors:  Joerg Latus; Renate Lehmann; Meike Roesel; Peter Fritz; Niko Braun; Christoph Ulmer; Wolfgang Steurer; Dagmar Biegger; German Ott; Juergen Dippon; M Dominik Alscher; Martin Kimmel
Journal:  Endocrine       Date:  2013-01-20       Impact factor: 3.633

9.  Key role of the kidney in the regulation of fibroblast growth factor 23.

Authors:  Maria L Mace; Eva Gravesen; Jacob Hofman-Bang; Klaus Olgaard; Ewa Lewin
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

10.  Calcium deficiency reduces circulating levels of FGF23.

Authors:  María E Rodriguez-Ortiz; Ignacio Lopez; Juan R Muñoz-Castañeda; Julio M Martinez-Moreno; Alan Peralta Ramírez; Carmen Pineda; Antonio Canalejo; Philippe Jaeger; Escolastico Aguilera-Tejero; Mariano Rodriguez; Arnold Felsenfeld; Yolanda Almaden
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.